Andrea Viqueira

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 564 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

Tim H. Brümmendorf, Jörge E. Cortes, Dragana Milojković et al. · Leukemia · 2022 · 141 citations · Full text

Medicine, Hematology, Pharmacology +8

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Andreas Hochhaus, Carlo Gambacorti‐Passerini, Camille N. Abboud et al. · Leukemia · 2020 · 83 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

Michael H. Tomasson, Shinsuke Iida, Rubén Niesvizky et al. · HemaSphere · 2024 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Nizar J. Bahlis, Michael H. Tomasson, Mohamad Mohty et al. · Blood · 2022 · 52 citations

Medicine, Oncology, Pharmacology +14